Targeted treatment options for relapsed T-cell leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests different drug combinations based on the specific features of your leukemia cells. The goal is to find a targeted treatment that may work better for your T-cell leukemia that has returned or is resistant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years or older (this study is only for teens under 18 in France).
- Your T-cell leukemia has come back (relapse) or has not responded to standard treatments (refractory).
- You have had at least two lines of chemotherapy if your leukemia is resistant, or a first relapse within 24 months of remission.
- A blood or bone marrow sample must be sent to a special lab in France, Spain, or the Netherlands to check for a targeted drug option.
- You are able to care for yourself most of the time (ECOG score 0-3).
- You are not in palliative care and have no active other cancer or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This trial tests a combination of drugs (venetoclax, homoharringtonine, cytarabine, and g-CSF, called VHAG) for people whose T-cell acute leukemia or lymphoma has come back or hasn't responded to treatment. It aims to see if this combination can help when other treatments haven't worked.
Hear when a new LAL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.